Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

(2019) Nataliya Volkova et al.   Journal of Cystic Fibrosis

Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials

(2019) Gwyneth Davies et al.   Journal of Cystic Fibrosis

Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy

(2019) Alex H. Gifford et al.   Journal of Cystic Fibrosis

Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp- CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting

(2018) Dominique Hubert et al.   Journal of Cystic Fibrosis

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

(2018) Leona Bessonova et al.   THORAX

Data Resource Profile: The UK Cystic Fibrosis Registry

(2017) David Taylor-Robinson et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers

(2017) Nicola J Rowbotham et al.   THORAX

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

(2015) Gregory S. Sawicki et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial

(2015) Alexandra Quittner et al.   Health and Quality of Life Outcomes

Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes

(2013) Gregory S. Sawicki et al.   Journal of Cystic Fibrosis

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D- CFTR mutation and preserved spirometry: a randomised controlled trial

(2013) Jane Davies et al.   Lancet Respiratory Medicine

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

(2012) Philip H. Quanjer et al.   EUROPEAN RESPIRATORY JOURNAL

A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation

(2011) Bonnie W. Ramsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

High treatment burden in adults with cystic fibrosis: Challenges to disease self-management

(2008) Gregory S. Sawicki et al.   Journal of Cystic Fibrosis